UA116471C2 - Дозована форма антагоніста рецептора прогестерону - Google Patents

Дозована форма антагоніста рецептора прогестерону

Info

Publication number
UA116471C2
UA116471C2 UAA201510932A UAA201510932A UA116471C2 UA 116471 C2 UA116471 C2 UA 116471C2 UA A201510932 A UAA201510932 A UA A201510932A UA A201510932 A UAA201510932 A UA A201510932A UA 116471 C2 UA116471 C2 UA 116471C2
Authority
UA
Ukraine
Prior art keywords
dosage form
receptor antagonist
progesterone receptor
directed
antagonist dosage
Prior art date
Application number
UAA201510932A
Other languages
English (en)
Inventor
Барбара Шютт
Маркус-Гіллерт Шульце-Мосгау
Андреас КАЙЗЕР
Original Assignee
Байєр Фарма Акцієнгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48050601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA116471(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байєр Фарма Акцієнгезелльшафт filed Critical Байєр Фарма Акцієнгезелльшафт
Publication of UA116471C2 publication Critical patent/UA116471C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується застосування фармацевтичної композиції, що включає (11β,17β)-17-гідрокси-11-[4-(метилсульфоніл)феніл]-17-(пентафторетил)естра-4,9-дієн-3-он у дозуванні приблизно від 1,0 до 5 мг для лікування та/або профілактики гінекологічних захворювань, таких, як фіброзна пухлина матки (міома, лейоміома матки), ендометріоз або надмірна менструальна кровотеча.
UAA201510932A 2013-04-11 2014-04-09 Дозована форма антагоніста рецептора прогестерону UA116471C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13163417 2013-04-11
PCT/EP2014/057101 WO2014166971A1 (en) 2013-04-11 2014-04-09 Progesterone receptor antagonist dosage form

Publications (1)

Publication Number Publication Date
UA116471C2 true UA116471C2 (uk) 2018-03-26

Family

ID=48050601

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201510932A UA116471C2 (uk) 2013-04-11 2014-04-09 Дозована форма антагоніста рецептора прогестерону

Country Status (35)

Country Link
US (2) US20160296534A1 (uk)
EP (1) EP2983671B1 (uk)
JP (2) JP6486900B2 (uk)
KR (1) KR102198059B1 (uk)
CN (2) CN105120873A (uk)
AP (1) AP2015008778A0 (uk)
AR (1) AR095834A1 (uk)
AU (1) AU2014253153B2 (uk)
BR (1) BR112015025706A2 (uk)
CA (1) CA2909121C (uk)
CL (1) CL2015003014A1 (uk)
CY (1) CY1121190T1 (uk)
DK (1) DK2983671T3 (uk)
EA (1) EA032481B1 (uk)
ES (1) ES2708351T3 (uk)
HK (1) HK1218069A1 (uk)
HR (1) HRP20190141T1 (uk)
HU (1) HUE042368T2 (uk)
IL (1) IL241815B (uk)
LT (1) LT2983671T (uk)
MA (1) MA38465A1 (uk)
MX (1) MX363979B (uk)
MY (1) MY188267A (uk)
PH (1) PH12015502326A1 (uk)
PL (1) PL2983671T4 (uk)
PT (1) PT2983671T (uk)
RS (1) RS58277B1 (uk)
SG (1) SG11201507935TA (uk)
SI (1) SI2983671T1 (uk)
TN (1) TN2015000454A1 (uk)
TR (1) TR201900954T4 (uk)
TW (2) TW201932116A (uk)
UA (1) UA116471C2 (uk)
WO (1) WO2014166971A1 (uk)
ZA (1) ZA201801736B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000482A1 (en) * 2015-05-18 2019-04-12 Bayer Pharma AG Selective progesterone receptor modulator (sprm) regimen.
EP3214092A1 (en) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DK0792152T3 (da) 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Fremgangsmåder til svangerskabsforebyggelse
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
AU2005265357B2 (en) 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
HUE042368T2 (hu) 2019-06-28
TW201517910A (zh) 2015-05-16
LT2983671T (lt) 2019-02-11
TWI672142B (zh) 2019-09-21
SI2983671T1 (sl) 2020-06-30
CL2015003014A1 (es) 2016-04-15
PL2983671T3 (pl) 2019-04-30
RS58277B1 (sr) 2019-03-29
AU2014253153A1 (en) 2015-10-15
PT2983671T (pt) 2019-02-25
KR102198059B1 (ko) 2021-01-05
NZ712670A (en) 2020-10-30
AU2014253153B2 (en) 2019-05-30
CN110051619A (zh) 2019-07-26
PL2983671T4 (pl) 2019-04-30
AR095834A1 (es) 2015-11-11
KR20150143595A (ko) 2015-12-23
MX363979B (es) 2019-04-08
PH12015502326A1 (en) 2016-02-10
SG11201507935TA (en) 2015-10-29
TR201900954T4 (tr) 2019-02-21
JP6486900B2 (ja) 2019-03-20
EA201501011A1 (ru) 2016-08-31
US20160296534A1 (en) 2016-10-13
WO2014166971A1 (en) 2014-10-16
MA38465A1 (fr) 2017-02-28
IL241815B (en) 2019-11-28
BR112015025706A2 (pt) 2017-07-18
EA032481B1 (ru) 2019-06-28
EP2983671A1 (en) 2016-02-17
US20220143045A1 (en) 2022-05-12
TW201932116A (zh) 2019-08-16
JP6691193B2 (ja) 2020-04-28
ZA201801736B (en) 2019-07-31
JP2016515639A (ja) 2016-05-30
HRP20190141T1 (hr) 2019-03-22
JP2019034969A (ja) 2019-03-07
CA2909121C (en) 2021-02-09
CA2909121A1 (en) 2014-10-16
EP2983671B1 (en) 2018-10-24
MX2015014264A (es) 2016-03-01
ES2708351T3 (es) 2019-04-09
TN2015000454A1 (en) 2017-04-06
HK1218069A1 (zh) 2017-02-03
CN105120873A (zh) 2015-12-02
CY1121190T1 (el) 2020-05-29
MY188267A (en) 2021-11-24
DK2983671T3 (en) 2019-02-18
AP2015008778A0 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
JO3732B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
PH12015501819A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
TN2020000009A1 (en) Estrogen receptor modulators
MY172530A (en) Method for treating gynecological diseases
EA201492238A1 (ru) Композиция мизопростола
TH163150B (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
TH163150A (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
NZ731834A (en) Compositions for use in treating heavy menstrual bleeding and uterine fibroids
GR1008129B (el) Βελτιωμενο φαρμακευτικο σκευασμα περιεχον εναν ανταγωνιστη της αλδοστερονης και μεθοδος για την παρασκευη αυτου
IN2013MU02366A (uk)